|1.||Mizugaki, Hidenori: 1 article (06/2015)|
|2.||Fujiwara, Yutaka: 1 article (06/2015)|
|3.||Yamada, Yasuhide: 1 article (06/2015)|
|4.||Tamura, Tomohide: 1 article (06/2015)|
|5.||Nokihara, Hiroshi: 1 article (06/2015)|
|6.||Nakamichi, Shinji: 1 article (06/2015)|
|7.||Nakamura, Osamu: 1 article (06/2015)|
|8.||Inukai, Eri: 1 article (06/2015)|
|9.||Kitazono, Satoru: 1 article (06/2015)|
|10.||Yamamoto, Noboru: 1 article (06/2015)|
06/01/2015 - "A phase I study of resminostat in Japanese patients with advanced solid tumors."
06/01/2015 - "Resminostat was safely administered to Japanese patients with advanced solid tumors. "
06/01/2015 - "Resminostat was administered to patients with advanced solid tumors on a 14-day cycle consisting of once-daily administration on days 1-5. The dose was initiated at 400 mg and increased to 600 mg and then 800 mg. "
06/01/2015 - "This study was performed to evaluate the safety and determine the recommended dose (RD) of resminostat monotherapy, an oral histone deacetylase (HDAC) inhibitor, in Japanese patients with advanced solid tumors. "
10/01/2013 - "This first-in-human dose-escalating trial investigated the safety, tolerability, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and pharmacodynamics of the novel histone deacetylase (HDAC) inhibitor resminostat in patients with advanced solid tumors. "
|2.||Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/01/2014 - "Out of these, more than 8 novel hydroxamic acid based HDACi i.e., belinostat, abexinostat, SB939, resminostat, givinostat, quisinostat, pentobinostat, CUDC-101 are in clinical trials and one of the drug vorinostat (SAHA) has been approved by US FDA for cutaneous T-cell lymphoma (CTCL). "
|1.||Histone Deacetylases (Histone Deacetylase)
|2.||Histone Deacetylase Inhibitors
|3.||Hydroxamic Acids (Hydroxamic Acid)
|4.||7- (4- (3- ethynylphenylamino)- 7- methoxyquinazolin- 6- yloxy)- N- hydroxyheptanamide
|6.||vorinostat (suberoylanilide hydroxamic acid)